Sensei Biotherapeutics Grants Stock Options to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Source: Newsfilter
Sensei Biotherapeutics Inc. saw its stock price drop by 11.39% as it crossed below the 5-day SMA.
The company granted stock options for a total of 2,319,893 shares to 17 new employees, including 1,239,305 shares to COO Anand Parikh, aimed at attracting talent and enhancing its competitive edge. The options have an exercise price of $27.22, matching the closing price on the grant date, and a vesting schedule designed to incentivize long-term employee retention. This move comes amid a broader market decline, with the Nasdaq-100 down 1.28% and the S&P 500 down 0.59%, indicating sector rotation.
This stock option grant reflects Sensei's commitment to building a strong team as it advances its PIKTOR program and completes clinical trials, which may position the company for future growth despite current market challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNSE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNSE
About SNSE
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company's lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously. PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation. Its pipelines include PIKTOR (PIK-201), PIKTOR (PIK-101) and Sapanisertib.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sensei Biotherapeutics Rebrands as Faeth Therapeutics
- Corporate Rebranding: Sensei Biotherapeutics has rebranded itself as Faeth Therapeutics, marking a significant strategic shift aimed at enhancing brand image and attracting greater investor interest.
- New Ticker Symbol: The company's stock is set to begin trading under the new ticker symbol “FTH” on the Nasdaq Capital Market on June 16, 2026, which is expected to enhance market visibility and liquidity.
- Website Launch: Faeth Therapeutics has also launched a new corporate website at www.faeththerapeutics.com, aimed at improving customer and investor engagement through a more modern online presence.
- Stock Performance: The company's stock surged by 19.15% to $15.49, reflecting positive market sentiment regarding the rebranding and future growth prospects.
See More
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Latest Wall Street Ratings Overview
- SpaceX Initiation: New Street initiates SpaceX with a buy rating, projecting a 75% market share in a $2.3 trillion market, suggesting a fair value of $330 per share if the company captures 50% of the high-end market estimate, indicating strong potential in the space industry.
- Intel Double Upgrade: Bank of America upgrades Intel from underperform to buy, citing increased confidence in its opportunities in leading-edge wafers and packaging, which is expected to enhance its share in the larger CPU market, reflecting a positive outlook for the semiconductor sector.
- AMD Price Target Increase: Bank of America raises AMD's price target from $500 to $560, highlighting its leading position in the CPU market and the upcoming AI Day (Venice launch), indicating strong performance driven by technological innovation and market demand.
- Netflix Outperformance: Evercore ISI reiterates Netflix as outperform, with surveys showing robust core metrics in both U.S. and UK markets, particularly in the adoption of ad-supported subscription offerings, demonstrating its solid position in the competitive streaming market.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Sensei Biotherapeutics Reports Significant Q1 Losses Amid Pipeline Developments
- Escalating Financial Losses: Sensei Biotherapeutics reported a net loss of $170.24 million for Q1 2026, translating to $131.45 per share, nearly doubling from a loss of $6.9 million or $5.45 per share in the same quarter last year, primarily driven by $133 million in IPR&D expenses from the acquisition of Faeth Therapeutics.
- Surge in R&D Expenses: R&D expenses reached $17.95 million in Q1 2026, a significant increase from $3.72 million in 2025, indicating the company's ongoing commitment to drug development despite the short-term financial strain.
- Cash Reserves Status: As of March 31, 2026, Sensei held $202.8 million in cash, cash equivalents, and marketable securities, providing sufficient liquidity to support ongoing research activities despite the increased losses.
- Clinical Trial Progress: The company is conducting a Phase 1b/2 trial for PIKTOR targeting HR+/HER2- advanced breast cancer, with the first patient dosed in April and interim data expected in 2027, showcasing the company's potential in cancer treatment.
See More
Sensei Biotherapeutics Reports Q1 2026 Financial Results and Clinical Updates
- Clinical Trial Progress: In April 2026, Sensei Biotherapeutics dosed the first patient in its Phase 1b/2 trial for HR+/HER2- advanced breast cancer, with interim data expected in 2027, marking a significant advancement in the company's oncology pipeline.
- Financial Position Change: As of March 31, 2026, the company reported cash and cash equivalents of $202.8 million, a substantial increase from $21.2 million as of December 31, 2025, reflecting the positive impact of the capital infusion from the acquisition of Faeth Therapeutics on the company's financial health.
- Surge in R&D Expenses: Research and development expenses for Q1 2026 reached $18 million, a dramatic rise from $3.7 million in Q1 2025, primarily due to the inclusion of Faeth's R&D operations and one-time costs associated with the acquisition, indicating the company's ongoing commitment to drug development.
- Widening Net Loss: The net loss for Q1 2026 was $170.2 million, or $131.45 per share, significantly higher than the $6.9 million loss and $5.45 per share loss reported in Q1 2025, highlighting the financial pressures faced by the company as it expands its R&D and market presence.
See More
Sensei Biotherapeutics Rebrands as Faeth Therapeutics
- Corporate Rebranding: Sensei Biotherapeutics has rebranded itself as Faeth Therapeutics, marking a significant strategic shift aimed at enhancing brand image and attracting greater investor interest.
- New Ticker Symbol: The company's stock is set to begin trading under the new ticker symbol “FTH” on the Nasdaq Capital Market on June 16, 2026, which is expected to enhance market visibility and liquidity.
- Website Launch: Faeth Therapeutics has also launched a new corporate website at www.faeththerapeutics.com, aimed at improving customer and investor engagement through a more modern online presence.
- Stock Performance: The company's stock surged by 19.15% to $15.49, reflecting positive market sentiment regarding the rebranding and future growth prospects.
See More
Biotech Company Movements Analysis
- TherapeuticsMD Strategic Review: TherapeuticsMD (TXMD) saw its shares soar over 20% as the company evaluates various strategic alternatives including acquisitions and mergers, with Q1 net income reaching $103,000, a significant turnaround from a $636,000 loss last year, indicating potential for transformation.
- Sensei Biotherapeutics Clinical Progress: Sensei Biotherapeutics (SNSE) experienced a 20.48% stock increase driven by optimism surrounding its key clinical trial; the drug PIKTOR is currently in a Phase 1b/2 trial for HR+/HER2- breast cancer, with interim data expected in 2027, which could present significant market opportunities.
- Shattuck Labs Crohn's Disease Trial: Shattuck Labs (STTK) shares rose 18% as its candidate SL-325 demonstrated safety in a Phase 1 trial, with plans to initiate a Phase 2 trial for Crohn's disease in Q3 2026, potentially opening new treatment avenues for the company.
- Alumis NDA Submission Progress: Alumis (ALMS) saw a 15.55% increase in stock price, with its lead drug Envudeucitinib undergoing a pivotal Phase 2b study for systemic lupus erythematosus, and an NDA submission expected in Q4 2026, marking a significant advancement in the treatment of immune-mediated diseases.
See More
Latest Wall Street Ratings Overview
- SpaceX Initiation: New Street initiates SpaceX with a buy rating, projecting a 75% market share in a $2.3 trillion market, suggesting a fair value of $330 per share if the company captures 50% of the high-end market estimate, indicating strong potential in the space industry.
- Intel Double Upgrade: Bank of America upgrades Intel from underperform to buy, citing increased confidence in its opportunities in leading-edge wafers and packaging, which is expected to enhance its share in the larger CPU market, reflecting a positive outlook for the semiconductor sector.
- AMD Price Target Increase: Bank of America raises AMD's price target from $500 to $560, highlighting its leading position in the CPU market and the upcoming AI Day (Venice launch), indicating strong performance driven by technological innovation and market demand.
- Netflix Outperformance: Evercore ISI reiterates Netflix as outperform, with surveys showing robust core metrics in both U.S. and UK markets, particularly in the adoption of ad-supported subscription offerings, demonstrating its solid position in the competitive streaming market.
See More
Replimune Receives FDA Support for BLA Resubmission
- BLA Resubmission Progress: Replimune Group Inc. announced an agreement with the FDA to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma within days, which is expected to boost the company's stock price and enhance market confidence.
- Patent Filing Success: Clearmind Medicine Inc. successfully filed a patent in Japan for its 5-Methoxy-2-aminoindan (MEAI) aimed at treating depression, strengthening its global intellectual property portfolio and potentially laying the groundwork for future market expansion.
- Clinical Data Update: C4 Therapeutics Inc. is set to present updated clinical data on Cemsidomide on June 12, 2026, which is anticipated to positively impact its application in treating multiple myeloma, further increasing investor interest in the company.
- Optimistic Financial Outlook: Alpha Teknova Inc. reported total revenue of $11.1 million for Q1 2026, a 13% increase year-over-year, and expects full-year revenue to range between $42 million and $44 million, indicating strong growth potential in the bioreagent market.
See More
Sensei Biotherapeutics Reports Significant Q1 Losses Amid Pipeline Developments
- Escalating Financial Losses: Sensei Biotherapeutics reported a net loss of $170.24 million for Q1 2026, translating to $131.45 per share, nearly doubling from a loss of $6.9 million or $5.45 per share in the same quarter last year, primarily driven by $133 million in IPR&D expenses from the acquisition of Faeth Therapeutics.
- Surge in R&D Expenses: R&D expenses reached $17.95 million in Q1 2026, a significant increase from $3.72 million in 2025, indicating the company's ongoing commitment to drug development despite the short-term financial strain.
- Cash Reserves Status: As of March 31, 2026, Sensei held $202.8 million in cash, cash equivalents, and marketable securities, providing sufficient liquidity to support ongoing research activities despite the increased losses.
- Clinical Trial Progress: The company is conducting a Phase 1b/2 trial for PIKTOR targeting HR+/HER2- advanced breast cancer, with the first patient dosed in April and interim data expected in 2027, showcasing the company's potential in cancer treatment.
See More
Sensei Biotherapeutics Reports Q1 2026 Financial Results and Clinical Updates
- Clinical Trial Progress: In April 2026, Sensei Biotherapeutics dosed the first patient in its Phase 1b/2 trial for HR+/HER2- advanced breast cancer, with interim data expected in 2027, marking a significant advancement in the company's oncology pipeline.
- Financial Position Change: As of March 31, 2026, the company reported cash and cash equivalents of $202.8 million, a substantial increase from $21.2 million as of December 31, 2025, reflecting the positive impact of the capital infusion from the acquisition of Faeth Therapeutics on the company's financial health.
- Surge in R&D Expenses: Research and development expenses for Q1 2026 reached $18 million, a dramatic rise from $3.7 million in Q1 2025, primarily due to the inclusion of Faeth's R&D operations and one-time costs associated with the acquisition, indicating the company's ongoing commitment to drug development.
- Widening Net Loss: The net loss for Q1 2026 was $170.2 million, or $131.45 per share, significantly higher than the $6.9 million loss and $5.45 per share loss reported in Q1 2025, highlighting the financial pressures faced by the company as it expands its R&D and market presence.
See More
